Conferencia de resultados del 3T de 2026 de Tandem Diabetes Care (TNDM): crecimiento de ingresos, mejora de márgenes y Mobi Tubeless

Puntos clave

• Tandem Diabetes Care registró unos ingresos mundiales de 284 millones de dólares en el 3T de 2026, lo que representa un aumento interanual del 14%, impulsado por un incremento del 12% en los envíos de bombas, hasta situarse en aproximadamente 33.000 unidades.
• El margen bruto alcanzó el 57%, casi 3 puntos porcentuales más en comparación con el año anterior. El margen de EBITDA ajustado se situó en el 6%, lo que marca el quinto trimestre consecutivo con un EBITDA ajustado positivo.
• Los ingresos en Estados Unidos aumentaron un 9%, hasta alcanzar los 191 millones de dólares. El canal de farmacia representó el 15% de las ventas en Estados Unidos, mientras que la cobertura en vademécum alcanzó aproximadamente el 50% de las vidas cubiertas.
• Los ingresos internacionales aumentaron un 26%, hasta alcanzar la cifra récord de 93 millones de dólares (un 27% a tipo de cambio constante), impulsados por el lanzamiento de productos, la ejecución comercial en mercados directos y los pedidos de suministros diferidos del 2T.
• La dirección mantuvo sus previsiones de ingresos mundiales para 2026 de entre 1.065 millones y 1.085 millones de dólares, así como una estimación para el margen de EBITDA ajustado del 5% al 6%.
• Tandem considera que Mobi Tubeless se encuentra en las fases finales de revisión por parte de la FDA y prevé obtener la autorización en el 4T de 2026, a lo que seguirá su plena disponibilidad comercial en el primer semestre de 2027. El calendario regulatorio continúa sujeto a la revisión de la FDA.

Datos financieros clave

Rendimiento comercial y operativo

El crecimiento en Estados Unidos reflejó una mayor demanda de bombas, los precios en el canal de farmacia y una creciente adopción en este canal. Las incorporaciones de nuevos clientes volvieron a registrar un crecimiento interanual, y las conversiones procedentes de inyecciones diarias múltiples representaron aproximadamente el 70% de los nuevos usuarios. La dirección señaló que las conversiones desde MDI crecieron casi un 10%, mientras que las renovaciones aumentaron a un ritmo de dos dígitos.

El modelo de farmacia PayGo generó el 15% de las ventas en Estados Unidos en el 3T. El canal de farmacia representó aproximadamente el 12% de los envíos de bombas y el 7% de la base instalada que realiza pedidos. El precio neto recurrente de los suministros se mantuvo por encima de la referencia mensual de 350 dólares de la empresa y promedió una cifra más cercana a los 400 dólares, aunque la dirección advirtió de que esto refleja únicamente datos de dos trimestres y un volumen limitado.

El rendimiento internacional se benefició del despliegue de Mobi, los pedidos iniciales de aprovisionamiento de AutoSoft+ y las operaciones comerciales directas. Los envíos en mercados directos aumentaron un 30% respecto al trimestre anterior, mientras que las ventas del canal directo representaron aproximadamente el 18% de los ingresos internacionales del 3T. Tandem espera atender de forma directa a más del 30% de su base instalada internacional tras iniciar operaciones en Francia, y prevé ampliar esa proporción hasta cerca de la mitad para finales de 2027.

Mobi Tubeless está diseñado como una opción de administración automatizada de insulina sin tubos para siete días que utiliza la bomba recargable Mobi existente. Los usuarios actuales de Mobi podrán alternar entre configuraciones con tubo y sin tubo simplemente cambiando los suministros. La solicitud inicial presentada ante la FDA se centra en el uso abdominal, y Tandem planea solicitar autorizaciones para otras zonas de colocación y tipos de insulina.

Tandem también inició el lanzamiento global de AutoSoft+, con una mayor expansión geográfica prevista para principios de 2027, sujeta a los requisitos regulatorios locales. Por su parte, el lanzamiento de SteadiSet, la tecnología patentada de equipos de infusión de la empresa autorizada para un uso de hasta siete días, está previsto para después de Mobi Tubeless.

Previsiones de la dirección

Para el 4T de 2026, la dirección prevé que entre el 15% y el 20% de las bombas y entre el 8% y el 10% de los pedidos de suministros de la base instalada se canalicen a través de farmacias, lo que representará casi el 15% de las ventas en Estados Unidos.

Para el conjunto de 2026, la dirección prevé ahora que tanto las bombas PayGo como la cuota de ventas del canal de farmacia se sitúen en torno al 10%-12% cada una, lo que refleja una adopción más lenta de lo previsto inicialmente. La empresa continúa apuntando a una transición hacia un modelo basado casi por completo en farmacias para finales de 2028.

Tandem no ha publicado previsiones formales para 2027. Sin embargo, la directora financiera, Leigh Vosseller, afirmó que un crecimiento interanual de los ingresos de un dígito medio a alto constituía un punto de partida razonable, dado que la adopción de bombas en el canal de farmacia avanza actualmente más rápido que la conversión de suministros, lo que genera un viento en contra estructural para los ingresos.

Riesgos y aspectos a vigilar

• La adopción del canal de farmacia avanza de forma más gradual de lo previsto inicialmente, a medida que los proveedores de salud, los clientes y los equipos comerciales de Tandem establecen nuevos flujos de trabajo para la prescripción.
• La adopción de bombas a través del canal de farmacia supera la conversión de suministros recurrentes, y la dirección prevé que el consiguiente impacto adverso en los ingresos se prolongue hasta 2027.
• La disponibilidad de equipos de infusión mejoró en el 3T, pero la dirección prevé que el impacto derivado de la escasez de proveedores continúe hasta principios de 2027.
• La transición a mercados directos internacionales redujo los ingresos del 3T en 3 millones de dólares y los ingresos acumulados en el año en aproximadamente 7 millones de dólares. Tandem prevé un impacto de 15 millones de dólares para el conjunto del ejercicio.
• Los plazos de autorización y lanzamiento de Mobi Tubeless siguen dependiendo de la revisión de la FDA, la ampliación de la capacidad de fabricación y la actualización de los contratos con farmacias.
• La eliminación del requisito del péptido C para determinadas personas con diabetes tipo 2 continúa sujeta a una decisión de los CMS.

Puntos destacados de la sesión de preguntas y respuestas con analistas

Plazos y cobertura de Mobi Tubeless: La dirección prevé que el producto comience con la cobertura de farmacia existente de Tandem de aproximadamente el 50% y señaló que las conversaciones con las entidades pagadoras continúan. Se contempla un uso limitado por parte de clientes tras la autorización, al que seguirá una plena disponibilidad comercial en el primer semestre de 2027.

Sistema de bucle completamente cerrado: Tandem prevé iniciar un estudio pivotal del algoritmo UVA AIDANET en el 4T de 2026. La dirección describió un ensayo con más de 300 y potencialmente 400 participantes que abarcará diabetes tipo 1, diabetes tipo 2 y adolescentes, con un seguimiento de tres meses para cada participante. La empresa espera contar con datos suficientes para presentar la solicitud a la FDA hacia finales de 2027 y apunta a un posible lanzamiento al mercado en 2028, sujeto a los resultados del estudio y del proceso regulatorio.

Aspectos económicos del canal de farmacia: La dirección indicó que el precio de los suministros recurrentes se sitúa actualmente más cerca de los 400 dólares al mes, por encima de su referencia base de 350 dólares. Sin embargo, instó a la prudencia, ya que las nuevas incorporaciones contractuales, el bajo volumen actual y el escaso historial operativo podrían afectar al rendimiento económico futuro.

Transición en el liderazgo: John Sheridan se jubilará a finales de 2026 tras ocho años como director ejecutivo. Está previsto que Jeannette Bankes se incorpore a Tandem como presidenta y directora ejecutiva el 16 de noviembre, aportando más de 30 años de experiencia operativa global en tecnología médica.

Transcripción completa de la conferencia de resultados

Transcripción completa de la conferencia de resultados

Comentarios de la dirección

Operator

Good day, and welcome to the Tandem Diabetes Care Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note, this call may be recorded.

I would now like to turn the call over to Susan Morrison, Executive Vice President and Chief Administrative Officer. Please go ahead.

Susan Morrison

Hello, and welcome to Tandem's 2026 Third Quarter Earnings Call.

Today's discussion will include forward-looking statements, including statements about our CEO transition and its timing, our leadership, strategy, product pipeline, development time lines, financial performance, including profitability and operating plans and speak only as of today's date. These statements reflect our current expectations about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements, which are described in our press release issued earlier today and under the Risk Factors portion of our most recent annual report on Form 10-K and quarterly report on Form 10-Q as well as the Form 8-K we issued today.

Today's discussion will also include references to both GAAP and non-GAAP financial measures. Please refer to our earnings release issued today and available on the Investor Center portion of our website for a reconciliation of non-GAAP measures to their most directly comparable GAAP financial measure and other information regarding our use of non-GAAP financial measures.

In addition, we also issued a press release this afternoon on the planned evolution of Tandem's CEO leadership. To speak to this announcement, the Chair of Tandem's Board of Directors, Beckie Robertson, will join us in opening today's call. We'll then move to our third quarter earnings results and company update from John Sheridan, President and CEO; and Leigh Vosseller, Executive Vice President and Chief Financial Officer. After their prepared remarks, we'll open the call for questions with John and Leigh. Thank you in advance for limiting yourself to one question before we joining the queue.

I'll now turn the call over to Beckie.

Rebecca Robertson

Thanks, Susan, and good afternoon, everyone.

Today's succession announcement marks an important milestone for Tandem Diabetes Care. As part of a planned leadership transition, we celebrate John Sheridan's accomplished tenure as he prepares to retire at the end of 2026, and we are thrilled to welcome Jeannette Bankes as Tandem's next President and CEO.

On behalf of the Board, I want to thank John for more than a decade of service to Tandem, including 8 years as CEO. Under John's leadership, Tandem has grown into a global innovator in diabetes care. He launched Control-IQ, our first hybrid closed-loop technology, advanced our digital health strategy and expanded our portfolio with the introduction of Mobi. In addition, he established the foundation for Tandem to operate at scale internationally and set in motion business model changes that broaden customer access. Just as important, he cultivated a mission-driven culture that will continue to define this company.

With this foundation in place, Jeannette is the right leader to guide Tandem through its next phase of growth. Jeannette stood out during the Board succession planning and search process, bringing more than 30 years of global operating experience and an impressive record of translating strategy into consistent execution and growth. Her experience scaling medical technology businesses is well suited for Tandem at this stage as we capitalize on our new business model and expand internationally. Jeannette's customer-centric approach, broad perspective and commitment to innovation align closely with Tandem's culture, mission and priorities as we advance our technology road map, expand customer access and pursue sustainable growth and profitability. She is also well positioned to shape Tandem's long-term strategy and strengthen our competitive position.

Throughout the transition, our leadership team remains focused on Tandem's strategic priorities, and the Board is confident in the organization's ability to deliver. John, thank you again for your leadership and your commitment to Tandem. Jeannette, we are excited to welcome you to the company on November 16.

With that, I'll turn the call over to John.

John Sheridan

Thank you, Beckie, and welcome, everyone, to our call today.

It's been an honor to work alongside such an incredible group of employees and the Board since 2013 and to have the privilege of leading this company for the past 8 years. Together, we furthered Tandem's mission to improve the lives of people with diabetes. I am proud of all that we've accomplished, especially that 0.5 million people worldwide now benefit from Tandem's technology.

Tandem's fundamentals are strong, and I am confident in its future under Jeannette's leadership. She brings the experience, perspective and commitment needed to build upon our momentum, and I look forward to supporting her through a smooth transition. Our team remains focused on executing our strategy and delivering value for our customers and shareholders. And with that, let's review our earnings results and the progress we're making across the business.

Looking back on the third quarter and our year-to-date performance, I am proud of what Tandem has accomplished in 2026. We're executing on our strategic priorities to expand access to Tandem's life-changing technology while strengthening our business model, advancing our pipeline and driving efficiency in our operations. These efforts are delivering tangible results. We outperformed across the P&L with increased contribution from our U.S. pharmacy transition and international shift to direct operations. Q3 also marked a quarter of record sales in pump shipments with both growing double digits worldwide. This was supported by enhanced pricing and a return to year-over-year growth in U.S. new pump starts and strong early demand for Tandem Mobi in the 12 countries where it's now available internationally.

Beyond top line growth, we're delivering significant margin expansion. This reflects focused execution on our efficiency initiatives and a balance between cost discipline and investment in growth. These recent accomplishments provide a solid foundation that positions Tandem for long-term success. Today, we'll provide more color on these results and review progress against our strategic priorities.

Starting with reshaping our business model, we are undergoing major shifts in our approach to the global markets. In the U.S., after just 2 full quarters under PayGo reimbursement model, pharmacy sales have reached 15% of U.S. sales. We have steadily expanded access across the year and already achieved the high end of our full year target with approximately 50% formulary coverage. Early results in pharmacy demonstrate that the model is positioning us to achieve our goals of reaching more people through simplified access with lower upfront costs while driving greater economic benefit for our business.

Outside the United States, we launched direct commercial operations in the U.K., Switzerland and Austria earlier in the year and remain on track to do the same in France this week. As one of our larger European markets, France represents an important next step for our international strategy. With this addition, we will be serving more than 30% of our international installed base directly. We plan to continue expanding our direct operations across 2027, which expands our footprint to approximately half of our installed base by the end of next year. Our early experience with direct international operations in 2026 confirms the strategic benefits of this approach as we develop closer relationship with customers and health care providers while achieving greater economic value.

Turning to our pipeline advancements. We believe Tandem Mobi Tubeless is in the late stages of FDA review. Mobi Tubeless is designed to be the world's first and only tubeless AID system offering up to 7 days of wear. This new infusion site option converts an existing Mobi pump into a tubeless system. Users can switch between tubed and tubeless wear with the same rechargeable pump just by changing their supplies. Combining Control-IQ's best-in-class A1c outcomes with tubeless wear positions Tandem to compete in the fastest-growing segment of the pump market with more wear options than any other system.

Following clearance, we plan to begin a scaled commercial launch, expanding manufacturing capacity and updating pharmacy contracts. We're also excited to introduce health care providers to Mobi Tubeless and pending clearance are preparing to begin limited customer use and then expand to full commercial availability in the first half of 2027. To speed time to market, our initial submission focused on abdominal wear and we'll be working with the FDA to add more wear locations and insulin types.

We also continue to innovate across our portfolio. Infusion set technology remains a key focus as we seek to improve comfort, extend wear time, reduce occlusions and simplify the user experience. In Q3, we initiated a global launch of AutoSoft+, a new infusion set from our third-party supplier that is designed to improve ease of use with reliable one-hand insertion. AutoSoft+ is now available in select countries, and we plan to expand to additional geographies in early 2027, pending any in-country regulatory requirements. This timing is important as we continue to manage supplier shortages of other infusion sets. We saw improved supply availability in Q3 and although improving, some level of impact remain into early 2027.

We also plan to launch SteadiSet following Mobi Tubeless, our proprietary technology that is FDA cleared for wear up to 7 days, further expanding our customers' choice in infusion sets. We also took meaningful steps in Q3 to progress our automated insulin delivery efforts. The pursuit of an algorithm worthy of the term artificial pancreas has been foundational to our vision. And as we shared in the last call, Tandem is closer than ever to this achievement.

Building on our long-standing research partnership with the University of Virginia, Tandem is developing UVA's next-generation AIDANET algorithm into a fully closed-loop system. The system is designed to help people with type 1 and type 2 diabetes reach clinical time and range targets without real announcements or other inputs while still allowing users to enter additional information for a more personalized experience. We continue to advance the work necessary to begin a pivotal study before the end of 2026 in support of an FDA submission.

With that, I'll turn the call over to Leigh for more details on our third quarter financial performance.

Leigh Vosseller

Thanks, John.

As John outlined, our third quarter performance reflects significant progress across the business. We achieved many new Q3 records across sales, pump shipments and gross margin. Overall, the quarter provided further evidence that our strategy and business model initiatives are translating into meaningful results. I'll focus my remarks today on the key drivers behind our performance and what they indicate about the company's financial trajectory.

Starting with sales, worldwide revenue grew 14% year-over-year to $284 million. Pump shipments increased 12% to approximately 33,000 pumps. In the U.S., pump shipments increased 11% year-over-year to nearly 23,000. The trajectory of new customer starts continued to improve and return to growth during the quarter. MDI conversions represented approximately 70% of new customers and renewals grew at a double-digit rate. Together, these results reinforce our confidence that our product innovation, business model changes and commercial investments are expanding the insulin pump market.

U.S. sales increased 9% year-over-year to $191 million, driven by increased pump demand, pharmacy pricing and pharmacy adoption. The PayGo model remains a significant opportunity for our business, and we increased each of our key pharmacy metrics this quarter. Pharmacy grew meaningfully to 15% of U.S. sales in the third quarter. We also reached our year-end access goal early with approximately 50% of U.S. covered lives on formulary, and we expect Mobi Tubeless to be an important catalyst for further expansion. While the $0 pump in our PayGo model creates an initial revenue headwind, higher recurring supply revenue offset that impact this quarter with net supply ASPs again exceeding $350 per month ahead of our baseline expectations.

Pharmacy adoption increased to approximately 12% of pump shipments and 7% of our ordering installed base. Adoption is scaling, although the pace of transition is more gradual than we initially anticipated. The pace largely reflects the time required to establish new prescription workflows and change behaviors across our teams, health care providers and customers. Our number of health care providers prescribing through pharmacy has increased each month since launch, and we believe new pharmacy exclusive products, including Mobi Tubeless and AutoSoft+ will help accelerate adoption.

In the fourth quarter, we anticipate shipping approximately 15% to 20% of pumps and 8% to 10% of our installed base supplies through pharmacy, representing nearly 15% of U.S. sales. With the pace of pump adoption through pharmacy outpacing supply conversions, we anticipate continued sales headwinds extending into 2027. Importantly, the underlying indicators continue to strengthen, including formulary access, provider participation and recurring supply economics. We look forward to demonstrating what this model can do at greater scale across our sizable and growing installed base of nearly 330,000 customers.

Turning to our international performance. We shipped nearly 11,000 pumps and achieved our highest sales quarter ever at $93 million, up 26% year-over-year or 27% in constant currency. This performance was driven primarily by new product launches and strong execution in our direct markets, along with the anticipated benefit of supply orders deferred from the second quarter. The benefits of our transition to direct operations are also beginning to show with a 30% sequential increase in direct market shipments at meaningfully improved pricing. Direct channel sales represented approximately 18% of international revenue in the quarter and 14% year-to-date, keeping us on track for our full year expectation of 15%. The quarter also included a $3 million headwind from our direct market transitions, bringing the year-to-date impact to approximately $7 million of the $15 million we expect for the full year.

Turning to margins. The actions we have taken to improve our margin profile are delivering results. Gross margin was 57%, improving nearly 3 percentage points year-over-year. This performance largely reflects pricing improvement from our global business model changes. Our supply margins hit a record high, improving by more than 10 percentage points in the last 2 years. We also continue to see the benefit of lower product costs with the increased adoption of Mobi in the market.

Operating expenses for the quarter were $163 million, up only 4% year-over-year as we maintained disciplined expense management while continuing to invest in our strategic growth priorities. SG&A increased, reflecting commercial investments worldwide, while R&D was flat. These increases were largely offset by a $5 million decline in stock-based compensation expense. With revenue growing significantly faster than expenses, we generated meaningful operating leverage, improving operating margin by 8 percentage points and adjusted EBITDA margin by 5 percentage points. Adjusted EBITDA reached 6% of sales, marking our fifth consecutive quarter of positive adjusted EBITDA.

We ended the quarter with a strong balance sheet at $443 million in cash and investments. Free cash flow reflected continued investment to rebuild infusion set inventory to our desired stocking levels and further invested in capital equipment to support upcoming product launches.

Turning to our 2026 expectations. We are encouraged by strong progress as we undergo our global business model transformation. Our performance year-to-date reinforces our confidence in the 2026 guidance. Worldwide sales are expected to be in the range of $1.065 billion to $1.085 billion. This includes U.S. sales in the range of $730 million to $745 million and international sales in the range of $335 million to $340 million. We expect gross margins in the range of 56% to 57% and adjusted EBITDA margin of 5% to 6% of annual sales.

In closing, I am proud of our execution this year and the strong third quarter results we delivered. This performance reinforces our confidence in the financial trajectory of the business and our 2026 outlook.

With that, I'll turn the call back to John.

John Sheridan

Thanks, Leigh.

In closing, our third quarter performance reflects solid execution against the priorities we set for the year and reinforces my confidence in Tandem's strategic direction. We are carrying meaningful momentum into the final months of 2026 with a clear focus on expanding customer access, advancing innovation and driving sustainable, profitable growth.

Before I close, I want to thank the entire Tandem team. Your focus, resilience and commitment to our customers have made this progress possible, and I am deeply grateful for everything that you do on behalf of Tandem and the diabetes community we serve.

I'll now turn the call over to the operator for questions.

Operator

[Operator Instructions] Our first question comes from Mathew Blackman with TD Cowen.

Preguntas y respuestas

Mathew Blackman

Can you hear me okay?

John Sheridan

We can.

Mathew Blackman

Great. Well, John, congratulations and best of luck on future endeavors. I'm just curious why now you feel like it's the right time to step aside. Obviously, a lot has been accomplished over the last couple of years, but also on the cusp of a lot of very exciting things ahead. So just your thinking of why now and what sort of the business looks like now that you're moving on. Just any thoughts there would be really helpful.

John Sheridan

Sure. Well, I'm not a spring chicken any longer. I'm 70 years old. I know I look like 60, but I'm 70, and I've got to make a decision at some point. And so I've been working with the Board and for quite a while now. And I think the things that I really cared about accomplishing this before I stepped down were Mobi Tubeless, the pharmacy channel, the OUS expansion and certainly the fully closed loop systems. And I think as we enter 2026, I feel very confident that these things are moving in the right direction. We're going to execute and a great deal of confidence.

And so the second thing you've got to do is you have to find somebody to replace me. And we've done a lot of searching on this, and we found an outstanding candidate with Jeannette Bankes. She's got great experience as a leader of multiple medical technology companies for many years. And more importantly, she's got a great -- she's got the, I'd say, the cultural awareness that's really important to our business, and she's very mission-driven. So she's capable. She's got a track record of executing on strategy. So I think that she's going to do a great job, and I look forward to supporting her for the next couple of months. And so it's really a matter of just there were some things I wanted to get done. I really feel confident that these things are going to get done, and we've got a great leader in Jeannette. And I'm rooting for the company as we go on into '27 and beyond.

Operator

Our next question comes from Matthew O'Brien with Piper Sandler.

Matthew O'Brien

John, let me echo Matt's congratulations on your retirement. Best wishes. Would love to hear about the pharmacy channel. I may have missed it with the number of earnings calls you have tonight, but 15% in Q3, that would mean you need to get, I think, 29% in Q4 to get to the 15% average for the year. So I don't think that's going to happen. What are we thinking as far as pharmacy revenue goes here full year now for '26? And then how do we think about that metric as we head into the totality of '27?

Leigh Vosseller

Yes. Great question, Matt. There's a lot to unpack there. So first, I'm just going to start at the very highest level and talk about the 3 major levers, I would say, that indicate our progress in pharmacy. And I'll start with access. And so we have reached about 50% coverage on formulary, and that's well ahead of our expectations. And that is really the most important in these early stages because that builds the opportunity for us.

The second lever would be pricing. And I would say that we are nicely outperforming the baseline expectation we set of $350 per month. It's actually averaging closer to $400 right now. We're asking that we keep our expectations tempered there at this time because it's only 2 quarters of data. We're continuously adding new contracts, and it's still really small volume. So we want to see how that plays out in the longer term, but performing very well in that regard.

And then the third measure of progress is the pace of adoption. And that's where I would say that it's been developing a little bit more gradually than we had originally anticipated. It is stepping up each quarter as we look ahead. And in the fourth quarter, we expect it to step up again, not going to reach those original assumptions that we put out there at the beginning of the year. But after 2 quarters of data, we feel like we have a more informed view of how to think about this looking ahead. And so we're still very confident in our ability to achieve what we've set up in the 2- to 3-year time frame that we said, which is by end of '28, we'll have this model turned over and be almost all pharmacy as opposed to DME. So things are on the right track there.

But you do ask a very important question, where do we go from here? And so as we look into the year, the assumptions now look more like about PayGo pumps for the year will be more like 10% to 12%. When you think about pharmacy as a percent of sales, it will probably average something more in the low teens, like also 10% to 12%. And that's just reflective of the fact that we have seen this more gradual pacing. And we are considering the fact that the pharmacy pump adoption has been slightly pacing faster than the conversion of the supply base. And so with that, that takes us into 2027, where we think about these headwinds we've talked about may shift into next year. And so with this new information about the pacing that we have in hand and that we've shared today, I expect that people will need to relook at their models for next year and recalibrate for this new information.

Operator

Our next question comes from Kieran Ryan with Deutsche Bank.

Kieran Ryan

Congrats to John. I just wanted to ask about Tubeless Mobi and some of the commentary and timing you get there. When you talk about commercial availability in the first half of '27, can you talk about how much of your current pharmacy formulary coverage would you expect to be live for Tubeless Mobi at that point and whether plans cover it under kind of existing Mobi arrangements or if that will be something that goes plan by plan? And I guess just kind of on a similar note, just wondering how a current Mobi user who accesses through DME might be able to access Tubeless Mobi?

Leigh Vosseller

Sure. So I'll take that question, actually. So the 50% coverage that we have today is the starting point for Mobi Tubeless. We're actually in additional conversations, and we expect to continue to increase the coverage by the time we get to full commercial availability. And in fact, Mobi Tubeless, we see and Mobi Tubeless and AutoSoft+ as pharmacy-only products are really a key driver into getting more throughput into the pharmacy channel, and they can be an accelerator for us on that pace of adoption. But Mobi Tubeless itself also is an important conversation point with the PBMs and the payers because they view this as very important to them for what they want to see in the pharmacy channel and much more directly competitive with the other tubeless option there. So the coverage is starting off where we are today already, and we expect to keep building on that across the year.

John Sheridan

And Kieran, if you have a Mobi pump today, all you really have to do is buy the tubeless supplies. It's an infusion plate and a cartridge that is designed to work with the infusion plate. And so it's a very easy transition to move from a tubed Mobi to a tubeless Mobi. And we expect people in the existing installed base will want to do that aggressively once it's on the market.

Operator

Our next question comes from Lawrence Biegelsen with Wells Fargo.

Larry Biegelsen

It's Larry. So I guess on Mobi Tubeless, John -- and by the way, congratulations. I really did think you were going to make it until you're 80, but do you expect clearance in Q4? Just what gives you the confidence you're in the late stages of review here? Why only abdominal wear? And what's the pathway to get other sites like the arm? And how do you think that limits commercial adoption just to have abdominal wear?

John Sheridan

Yes. I think that as you start to work with FDA on these filings, you have questions. And as you get towards the end, the questions change, and they really have to do with more about preparing for launch. And so we're definitely in that phase with them right now. And I think that we expect it to be approved in the fourth quarter. And then relative to how we submitted this, we submitted it to get it through the review process quickly. But in the process, we work with the FDA, and we let them know that we plan to make these changes and that they have mechanisms to allow us to agree ahead of time that these changes can occur and we define the test protocols and the results that we would expect to achieve. And we can continue to do that after we've received clearance. So those mechanisms out there that we intend to continue to follow to get -- we are going to launch this product with multiple locations and also with multiple insulins. And we think that we can do that in a relatively expedited manner.

Operator

Our next question comes from Steve Lichtman with William Blair.

Steven Lichtman

John, best of luck. It's good working with you. Just wondering on the fully closed loop. Any more details you can provide on what the pivotal trial will look like? And once you do begin it, if it is by the end of this year, potential timing on approval of that enhanced algorithm?

John Sheridan

Yes. So we have high confidence we're going to begin it in the fourth quarter. I'll just start off by saying that. It's going to be a large study. It will be type 1 and type 2 and adolescents. So it's going to be in excess of 300, maybe even 400 people. I think that the study is going to -- each person will have to go through 3 months. And we're in the process right now of contracting and getting patients ready for starting the study. It typically will take us 3 to 4 quarters to get through it. So we'll -- by the end of '27, we expect to have enough data to submit to the FDA. And that review process probably can take a quarter or 2. So I would say that in 2028, we expect to have the product in the market. We're very excited about it. We think we've got the best product that's coming to market. We have a great relationship with UVA. They've developed a really nice product. And we're really excited about it. And I think that as I said, we think this is going to be a game changer for the business.

Operator

Our next question comes from Jakub Mlejnek with OpCo.

Jakub Mlejnek

Congrats, John. Moving to the international growth acceleration there. You noted that moving direct brings at least the 30% pricing uplift alongside the renewal opportunity. So in the markets you've already transitioned, can you separate the contribution from patient demand pricing and maybe any catch-up shipments following the infusion set constraints? And then how much of the recorded growth is representative of the, I guess, underlying trajectory for next year?

Leigh Vosseller

Sure. Great questions there. So from an international perspective, I think you said it well, the things that were drivers. In the third quarter, in particular, we did have a small deferral of sales from the second quarter related to supply shipments that benefited the quarter. But I would say the biggest drivers were the new products as Mobi is being scaled up in its launch and also out-of-stock plus launching where distributors were actually ordering some of their first stocking orders for that product.

And so when we look at the strength, the direct markets are still a small percent of the business through the end of the third quarter. By the time we get to the end of the year, we should be servicing about 30% of our base in those direct markets. And so although small contribution at this time, the progress there is pretty exciting. Shipments in those markets increased 30% from Q2 to Q3. So we're just at the very beginning phases there.

So overall, without putting any hard numbers to it, there was contribution both from that volume increase in the direct and the distribution markets, but noticeably in the direct markets, as well as the pricing benefit we get from that uplift from being direct and then the new products just starting to generate more momentum. And so I think the international markets, at least for Tandem have been underappreciated by many, and I think you're going to start to see some really exciting stuff happen there as we continue on this journey.

John Sheridan

I would just add that Mobi is doing really, really well in the international market on early data. Very excited about how that's going to even further advance the growth.

Operator

Our next question comes from Joanne Wuensch with Citibank.

Unknown Analyst

This is Anthony on for Joanne. I think the answer is no, but this dynamic you're going through with a bit slower adoption of supplies through the pharmacy channel. Will that impact at all, you think the uptake of Mobi? And then if I could tack on a quick follow-up. What actions do you need to take just to drive more awareness that supplies are not available in the pharmacy?

Leigh Vosseller

Sure. A lot of good things about pharmacy and the adoption. And so first of all, maybe I'll talk about a few of the things that we think will impact or benefit pharmacy adoption in the near term. And some of it is just the early learnings as we've gone through the implementation, how the processes work, educating physicians. We're now at the size of amount of coverage where we can start more broadly marketing to the pharmacy channel. So those are all the areas where we can start to drive that momentum.

The coverage is at a really good level, and we expect to continue to see increased coverage by the time Mobi is fully available commercially. And so Mobi Tubeless is helping drive that conversation on coverage, but also with availability only in the pharmacy, it will help drive that volume through pharmacy. So we see that as not a limitation for people, but as a momentum builder, and it will keep pushing up to the level of coverage where we won't have this gap for people who don't have access immediately. And so as John mentioned earlier, people can buy their pump today and they can switch to tubeless supplies at any future date. And so we think this will bring a lot of good momentum to Mobi itself as a platform. And we do think this is actually will be a big help to our -- meeting our pharmacy goals.

Operator

Our next question comes from Ravi Misra with Truist Securities.

Ravi Misra

John, congratulations. It's Ravi here for Rich. So I just wanted to push a little bit on the FCL and big picture question around how you see this resonating with payers. Obviously, you're still fighting for coverage in that channel. But longer term, can you just help me understand, everyone has one of these algorithms coming out in a couple of years or so. Is it just kind of something you need to kind of be in the conversations with payers? Or is it something that, obviously, you can't argue on the merits just yet. Just help us understand a little bit how that strategy is there.

John Sheridan

Sure. I think fully closed loop is going to enable patients to get the same results or even better results that we're seeing today on hybrid closed loop systems without the work that goes along with it. So people who want to just set it and forget it can do that. And that's a substantial reduction in the burden of diabetes for those people. And I think as you look at the adoption of AID systems, early on, you had the early adopters who might be willing to interact with the system, maybe it's a little bit more technically required to interact with the system. But as we move through the curve, the growth curve, the people we're interacting with right now, including people with type 2 in particular, want to have a very simple experience. And so I think simplifying the experience of wearing a device for 24/7 is really, really important. And I think it's one of the main drivers to get to increased adoption rates of 65% plus, knowing that we're currently around 40%. So -- and we also -- again, I think the experience that people are going to have is going to be a real positive, and it's going to absolutely drive adoption for both type 1 and type 2 people living with diabetes.

Operator

[Operator Instructions] Our next question comes from Jon Block with Stifel.

Jonathan Block

Leigh, I might be doing something wrong, but it seems like based on your prior comments, roughly 10,000 pumps might now be going through pharmacy. I think you said 10% to 12% of the 94,000, 95,000 versus the 18,000 initially planned, the 20% of the 94,000, 95,000. So if you've got an extra 8,000 pumps going through DME and the upfront ASP, do you land at $32 million that now you're getting upfront on the pump side? I know you're foregoing something on the supplies, but it's late in the year. So you're not getting -- not foregoing a lot of months on the supply. So why is the overall guide unchanged? Why aren't we seeing that appear now that you've got more upfront dollars on the pump side of things?

Leigh Vosseller

Yes. Good question. So when we -- I mean, we look at the variables for this year, so there's always a number of factors that get embedded in guidance, right? You have to think about the market, the competition, the growth rates, all the usual parts and pieces. But with pharmacy, it's even more convoluted with all the variables that go into that. And so when we looked at it, the way we are thinking about it is we're focused very much on the pharmacy adoption piece. And so if we drive more volume through pharmacy, let's say, first, that's a bigger headwind on sales.

If it becomes DME instead of pharmacy, that's a revenue upside opportunity, if you want to call it that. And so for right now, we wanted to err on the side of considering outperformance on pharmacy could actually have a negative impact on sales. And so we want to monitor how these trends play out through the end of the quarter. And it's more important for us to make sure we get the revenue number right and the levers to get there are the parts that we're going to keep addressing as we get more trends and information through the pharmacy. So at this point, we're focusing on the fact that in the fourth quarter, we're anticipating 15% to 20% of shipments through pharmacy, and it will continue to have that type of headwind. That's what's factored into the guide.

Operator

Our next question comes from Mike Kratky with Leerink Partners.

Michael Kratky

John, congrats on the retirement. Great working with you and hope to see on the golf store some time. Maybe just on the preliminary outlook or how you think about the building blocks for 2027. I mean it looks like FactSet, if I'm looking at this right, consensus is showing about 12% top line growth next year. Does that sound reasonable? Or given the recalibration on the pharmacy ramp, is it fair to think maybe that's closer to high-single digits to start just since you won't have that ASP uplift later in the year?

Leigh Vosseller

Yes. Really great question. And I think you probably appreciate my normal answer at this time is to say it's too early to give numbers. But with the changes that we've conveyed today on pharmacy and that pace of adoption, I do think it's important to get people started in the right place. And thinking about, as I mentioned just on the last question, erring on the side of if the pace of the pump adoption is faster than the uptake on the supply adoption, which is that sustained headwind that we all know is coming and really looking forward to, we want to make sure we are not disappointing on the revenue side. And so I think you're in the ballpark there in the mid- to high-single digit increase year-over-year is probably a really fair starting point as we continue to gather more data and trends here in the fourth quarter and into the beginning of the first quarter before we get to our year-end earnings call. So I think that's the appropriate way to think about it.

But I think another thing I would just like to highlight, it's not just about the percentage growth on revenue. As we've already shown this year, we can be performing very well as a business in terms of new start growth, market share capture, all of those other factors being very competitive, especially as we look forward to being -- competing in the fastest-growing segment of the pump market next year. And so a lot of good things happening in the business, but the transition for pharmacy just has that structural effect on revenue, and it's probably a lot of words around a good place to start.

Michael Kratky

Yes. Understood on that side. And maybe just one follow-up, but I thought it was really encouraging to hear you talk about the returns in U.S. new customer starts growth this quarter. So can you just maybe clarify the magnitude that you saw in 3Q and what you've seen so far in 4Q to help bolster your confidence on the overall number?

Leigh Vosseller

So maybe I'll start with the look back. New starts have been pressured in I think middle of last year, 2025 is when we saw the greatest pressure on new starts, and we've steadily seen that improve. And last quarter, we were just on the cusp of breaking even. This quarter, we did return to growth. And underlying that, the key driver there would be the MDI conversions. And that's where we're seeing the greatest effect coming from Mobi in particular. And again, we think Mobi Tubeless is going to be a catalyst for the business in so many ways, whether it's just new pumpers coming to Tandem, whether it's pharmacy adoption. MDI have grown to about 70% of pump shipments. And in fact, this quarter, MDI grew nearly 10%. So it's a really good trend for us, and we look forward to continuing to push on that as we go into next year.

Operator

Our next question comes from Jayson Bedford with Raymond James & Associates.

Elaine Cui

This is Elaine on for Jayson. I have one on type 2. Now that the C-peptide deadline has passed, do you have any visibility into when that could be up for consideration again? And how does your type 2 strategy change if this requirement stays? Can just Tubeless Mobi and pharma get you to the same amount of uptake?

John Sheridan

I think that Tubeless Mobi, pharma, FreeStyle Libre are all absolutely head -- tailwinds, tailwinds that are going to help us really take advantage of the type 2 market. But C-peptide is a real problem. That being said, we feel very positive. I mean, like we feel very positive that this is going to take -- be taken care of. We're awaiting decisions from CMS. I don't think it's an if, it's a when. And I think certainly, we thought this was going to happen in the August time frame. My guess is the election has probably gotten away, and we hope to hear about this in the near future. But I think it's a very important step forward for people with type 2, and we're looking forward to seeing that happen. Thank you.

Operator

Our next question comes from Matt Taylor with Jefferies.

Matthew Taylor

John, congrats, if you can just take me with you, please. It's been great working with you. Maybe I'll just ask a big picture market growth question. We've had strong market growth here for a number of years. There's a lot of innovation coming from you and across the space. I was wondering if you think this is enough to accelerate market growth or just kind of sustain the kind of growth that we're seeing over the next couple of years? Maybe just get your thoughts on that.

John Sheridan

Yes. It's always difficult to sort of triangulate out to how it's going in the midst of the year. But I would just say, looking back in '25, I think all of the pump companies did quite well. And I think at the end of '25, penetration might have been high 30s, maybe 40%. We think it can get to 65%. And so there's still a huge opportunity for us out there. And I think you're right. I think that innovation drives adoption, ease of use drives adoption. And everybody is heading in that direction. So it's not only our competitors, but our partners are as well. I think what this does is it really provides great technology to help people living with diabetes, and we're participating in that. And I think that I do feel that the technology is great, and it's going to continue to provide new growth opportunities in this market.

Operator

Our next question comes from Jeff Johnson with R.W. Baird.

Jeffrey Johnson

John, I'll throw my congrats out there as well. As I said to a couple of CEOs retiring, I'm jealous at this stage in my career that you're making the jump. So good luck in that.

John Sheridan

Thank you, Jeff.

Jeffrey Johnson

Yes. So I've been jumping around calls here. If this question has been asked, just tell me, and I'll go back to the transcript. I don't need to waste time on answering the question. But for the AIDANET trial, I'm pretty sure you guys are going through a bolus optional kind of where you can or cannot bolus at mealtime. It's kind of up to the user. Just talk to me maybe about your thoughts on the importance of leaving a bolus option out there, especially in type 1 versus going to more of a fully forced closed loop as maybe some of your peers are doing either in type 1 or type 2.

John Sheridan

I would say that we have not said that yet. What we have said, though, is that we will allow people to make adjustments to the system to optimize the performance of the system. I think we believe it's going to be fully closed loop with the ability to make adjustments to the system in the event that you want to make -- you want to optimize the performance. So we haven't said a bolus optional at this point in time. And I think that as time comes on and goes on, we'll be more specific about some of the specific features that we plan to bring to market.

Jeffrey Johnson

Do you generally feel it's important at mealtime for a type 1 to be able to announce if they want. And if they don't, maybe they just accept a little bit lower time in range. I guess just as you go through that decision tree and think about the pivotal and then how you ultimately commercialize the system, what are your just general thoughts there?

John Sheridan

I think we want the system to provide the best performance. We want to see people get the highest time in range, highest A1c reduction. And so we're definitely evaluating and we have evaluated a number of features like that. But as I said, we really haven't been specific about what's going to be included in that final feature set that will be starting here in the fourth quarter in our clinical study.

Operator

I'm showing no further questions at this time. I'd like to turn the call back over to John Sheridan for closing remarks.

John Sheridan

Okay. Well, as this is my final earnings call as CEO, I just wanted to say again what an honor it's been to lead Tandem and to work alongside such an exceptional team. I am proud of everything that we've accomplished together, and I'm really confident in the company's future. So thanks for your support over the years, and thanks for joining the call today.

Operator

Thank you for your participation. You may now disconnect. Good day.